TRUSELTIQ is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement as detected by an FDA-approved test. This indication received accelerated approval based on overall response rate and duration of response.
ONGENTYS® is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing "off" episodes.
- Adverse Reactions of Opicapone (Ongentys) Opicapone (Ongentys) is an adjunctive therapeutic drug for Parkinson’s disease (PD). As a combination therapy with levodopa/carbidopa, it is indicated to reduce the occurrence of wearing-off phenomena in patients. Like all medications, understanding its potential adverse reactions and essential precautions is crucial for its safe and effective administration.
Jan 26, 2026, 10:50 GMT+08:00
- What are the Precautions for Opicapone (Ongentys) Administration? Opicapone (Ongentys) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease for the control of “off” episodes.
Jan 26, 2026, 10:42 GMT+08:00
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Diabetic Macular Edema (DME).
Macular Edema Following Retinal Vein Occlusion (RVO).
- Side Effects of Vabysmo (Faricimab) Vabysmo (faricimab) is a bispecific antibody drug that has shown promising efficacy in improving visual outcomes, but it is accompanied by a series of side effects and precautions that require vigilance.
Nov 25, 2025, 09:19 GMT+08:00
- What Are the Precautions for Using Vabysmo (Faricimab)? Vabysmo (faricimab) is a dual-pathway inhibitor approved in recent years, demonstrating significant therapeutic effects by simultaneously targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).
Nov 25, 2025, 09:16 GMT+08:00
DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.
- What are the Procurement Channels for Derabrutinib (Datroway)? Derabrutinib (Datroway) is a Trop-2-targeted antibody-drug conjugate (ADC) indicated for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received prior endocrine therapy and chemotherapy. As a prescription medication, the standardization of its procurement channels and the reliability of product authenticity directly affect treatment outcomes and patient safety.
Nov 26, 2025, 09:15 GMT+08:00
- Dosage and Administration of Datroway (Datopotamab Deruxtecan) Datroway (datopotamab deruxtecan) is a Trop-2-targeted antibody-drug conjugate developed by Daiichi Sankyo Co., Ltd., which was approved by the U.S. FDA in 2025. It is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have previously received endocrine therapy and chemotherapy.
Nov 25, 2025, 10:06 GMT+08:00
TRUSELTIQ is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement as detected by an FDA-approved test. This indication received accelerated approval based on overall response rate and duration of response.
ONGENTYS® is indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing "off" episodes.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Diabetic Macular Edema (DME).
Macular Edema Following Retinal Vein Occlusion (RVO).
DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.
VAFSEO is indicated specifically for the treatment of anemia due to chronic kidney disease in adult patients receiving dialysis for a minimum of three months.
- How to relieve the side effects of Gilteritinib (Xospata)? Side effect management of Lazertinib requires targeted measures based on specific reaction types, with key focus on the prevention and control of venous thromboembolism, skin reactions, and ocular toxicity.
501
2026-02-13 11:29:38 - What are the side effects of Gilteritinib (Xospata)? Gilteritinib (Xospata) is a FLT3 inhibitor. Its adverse reactions mainly involve the hematological system, cardiovascular system, digestive system, etc. Different management measures should be taken according to the severity. 501
2026-02-13 11:01:40
- Where to Buy Venetoclax Tablets Venetoclax is a targeted medication used for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia (AML). As a prescription drug, its purchase and use must be strictly under medical supervision. 501
2026-02-12 13:49:24
- Indications of Venetoclax Tablets Venetoclax is an innovative BCL‑2 inhibitor that plays an important role in the treatment of hematologic malignancies. 500
2026-02-12 13:46:30
- Side Effects of Mavacamten (Camzyos) Mavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), New York Heart Association (NYHA) functional class II–III, to improve functional capacity and symptoms. However, its use is associated with a range of potential risks, side effects, and strict medication management requirements that require close attention. 501
2026-02-12 13:16:41
- What are the precautions for mavacamten (Camzyos)? Mavacamten (Camzyos) is a novel cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) of New York Heart Association (NYHA) functional Class Ⅱ–Ⅲ. It provides a new therapeutic option for these patients by improving their functional capacity and symptoms. 503
2026-02-11 10:33:05
- Mechanism of Action of Valsartan Tablets (Diovan) Valsartan Tablets (Diovan) is a widely used angiotensin II receptor antagonist (ARB) in clinical practice, indicated mainly for the treatment of hypertension, heart failure, and reduction of cardiovascular risk post-myocardial infarction. 500
2026-02-10 13:00:51
- Important Dosage and Administration Information As an angiotensin II receptor antagonist, valsartan is widely used in the treatment of hypertension, heart failure, and post-myocardial infarction. Appropriate selection of dosage form, dose adjustment, and preparation method are critical to ensuring efficacy and medication safety. 501
2026-02-10 11:23:07
- Overview of Common Side Effects of Vibramycin As a broad-spectrum antibiotic, doxycycline (Vibramycin) demonstrates significant efficacy in treating a variety of infections, yet certain side effects may occur during its administration. 501
2026-02-09 11:06:11
- Indications of Entrectinib Entrectinib (Rozlytrek) is a targeted anticancer drug indicated for cancer patients with specific gene mutations. 502
2026-02-09 10:26:45
